Skip to main content

Table 1 Cumulative probability (95 % CI) of achieving first LDA/remission or sustained LDA/remission

From: Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

 

First time point at which 95 % CI did not overlap, day

Cumulative probability (95 % CI) of achieving the specified state according to the different indices

Month 6

Month 12

Abatacept + MTX

MTX alone

Abatacept + MTX

MTX alone

First LDA

DAS28

85

57.6 (50.9, 64.3)

43.5 (36.8, 50.3)

80.6 (75.2, 86.0)

67.6 (61.1, 74.0)

CDAI

85

60.5 (53.9, 67.1)

43.5 (36.8, 50.3)

83.3 (78.3, 88.4)

69.3 (63.0, 75.6)

First remission

DAS28

57

40.0 (33.4, 46.6)

27.3 (21.3, 33.3)

70.2 (63.9, 76.4)

50.4 (43.5, 57.3)

CDAI

225

22.9 (17.2, 28.5)

14.4 (9.6, 19.1)

48.4 (41.6, 55.2)

31.2 (24.8, 37.5)

First sustained LDA

DAS28

57

54.8 (48.0, 61.5)

33.0 (26.6, 39.4)

CDAI

57

58.6 (51.9, 65.2)

37.3 (30.8, 43.9)

First sustained remission

DAS28

113

38.6 (32.0, 45.2)

20.6 (15.1, 26.1)

CDAI

141

24.8 (18.9, 30.6)

10.5 (6.4, 14.7)

  1. Based on as-observed analyses for patients with data available at baseline, month 6 and month 12. Cumulative probability evaluated based on Kaplan–Meier estimation with corresponding 95 % CI. First remission/LDA was defined by the first visit when the patient reached remission/LDA according to DAS28 and CDAI scores. Sustained remission/LDA was defined as first remission or LDA status (according to DAS28 and CDAI scores) maintained at all subsequent visits up to month 12; patients who lost remission/LDA status were censored at the time of remission/LDA loss. CDAI Clinical Disease Activity Index, DAS28 Disease Activity Score 28, LDA low disease activity, MTX methotrexate